Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Edelmann, F; Wachter, R; Düngen, HD; Störk, S; Richter, A; Stahrenberg, R; Neumann, T; Lüers, C; Angermann, CE; Mehrhof, F; Gelbrich, G; Pieske, B; German "Competence Network Heart Failure".
Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline.
Cardiovasc Diabetol. 2011; 10(1):15-15 Doi: 10.1186/1475-2840-10-15 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

Co-authors Med Uni Graz: Pieske Burkert Mathias
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background: To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function. Methods: 3304 patients with heart failure from 9 different studies were included (mean age 63 +/- 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (>= 50%) and 994 patients in the whole cohort suffered from diabetes. Results: The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function. Conclusions: Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.
Find related publications in this database (using NLM MeSH Indexing): Aged -; Blood Pressure -; Cardiovascular Agents - therapeutic use; Comorbidity -; Cross-Sectional Studies -; Diabetes Complications - drug therapy; Female -; Female -; Glomerular Filtration Rate -; Guideline Adherence -; Heart Failure - drug therapy; Humans -; Kidney - physiopathology; Logistic Models -; Male -; Middle Aged -; Practice Guidelines as Topic -; Stroke Volume -; Systole -; Treatment Outcome -; Ventricular Dysfunction, Left - drug therapy; Ventricular Function, Left -